Prostate cancer is regularly diagnosed in men of all ages. In order to spread awareness of regular testing and education of this deadly disease, Cancer Treatment Centers of America (CTCA) is paring up with LabCorp and the National Football League Alumni Association (NFLA) to bring a series of events named “Prostate Pep Talk” to each of the CTCA’s locations featuring alumni and current players of the NFL. These events are designed to raise awareness that regular testing and education is necessary to optimal prostate health.
Along with the educational events, LabCorp is offering free screenings to the first 2,000 men who signed up for a PSA (Prostate Specific Antigen) test. PSA testing can indicate an anomaly within the prostate if testing comes back abnormal. When the 2,000 spots get filled up, LabCorp is offering a low cost fee of $25.00 for the PSA to be performed. Patient’s need to schedule the test within six months to still be eligible for the free or reduced price spots.This latest joint venture is a sign of CTCA’s commitment to patient care excellence.
Based in Boca Raton, Florida, CTCA has been offering cutting edge cancer care to it’s patients across the nation. There are five current facilities: Philadelphia, Atlanta, Chicago, Tulsa, and Phoenix that make the same commitment to treat the patient as a whole being: mind, body, and soul.CTCA offers the best in treatments including: precision cancer treatment, surgery, immunotherapy, chemotherapy, radiation, and genome testing. CTCA takes care of their patients from day one, offering supportive therapies for those going through treatment. CTCA even provides aftercare when a patient has completed their cancer treatment program. To read more about CTCA’s latest venture.
As the co-Founder, President, Chief Executive Officer, and Chairman of the Board of Seattle Genetics, Inc., Clay Siegall is at the forefront of cancer research. Seattle Genetics is a company, headquartered in Bothell, Washington, that creates cancer drugs using antibody-drug conjugates. Ever since the release of the drug Adcetris, which treats lymphoma and potentially other types of cancers, in 2012 the company’s stock has tripled in value.
Dr. Siegall has exhibited a passion throughout his career for helping patients that are suffering from cancer. He is a graduate of George Washington University where he earned his Ph.D. in Genetics. He began his professional career at Bristol-Myers Squibb Pharmaceutical Research Institute as a Senior Research Investigator. He was promoted to Principal Scientist during his time at this institute. He has also performed research at the National Cancer Institute where he was a Staff Fellow and Biotechnology Fellow.
Helping cancer patients and diligently performing scientific research lies at the heart of Dr. Clay Siegall’s career. His cancer drug, Adcetris, is now being used in 60 countries and has helped saved many thousands of lives. He also has several more cancer drugs in the pipeline and is researching Adcetris’s promising potential to cure more types of cancer.
Due to Dr. Siegall’s leadership, Seattle Genetics has raised over $1.2 billion in funding from both the public and private sectors. This money has been used to hire more research staff, pay for more drug styles, and used to acquire the latest lab technology.
Dr. Siegall’s depth of knowledge and acumen has led to his acquiring 15 patents and having more than 70 scientific articles published.
As the leader of Seattle Genetics, Clay Siegall is responsible for the day-to-day operations of the company. He also is responsible for developing strategic partnerships with other companies. With Adcetris, Seattle Genetics markets and distributes it in the U.S. and Canada while Takeda Pharmaceutical Company does the same in the rest of the world. Dr. Siegall has also formed relationships with other companies such as Genentech, Pfizer, Abbvie, and GlaxoSmithKline.